Evaluation Of Drug Benefits Needs Quantitative Measures, FDA's Graham Says
This article was originally published in The Pink Sheet Daily
Evidence-based standards currently applied to risk should be applied to benefit, the FDAer adds.
You may also be interested in...
Industry will collaborate with FDA on ways to communicate risk/benefit information to patients, physicians and lawmakers, Pfizer Senior VP Corr says.
FDA's Pulmonary-Allergy Drugs Advisory Committee will vote July 13 whether currently available data support continued marketing of the long-acting beta-agonist bronchodilators. Committee will also consider labeling changes for formoterol concerning severe asthma exacerbations.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter